Driving assessment in preclinical Alzheimer’s disease: progress to date and the path forward
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Driving assessment in preclinical Alzheimer’s disease: progress to date and the path forward ; volume:14 ; number:1 ; day:8 ; month:11 ; year:2022 ; pages:1-4 ; date:12.2022
Alzheimer's research & therapy ; 14, Heft 1 (8.11.2022), 1-4, 12.2022
- Creator
-
Bayat, Sayeh
Roe, Catherine M.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-022-01109-1
- URN
-
urn:nbn:de:101:1-2023012209244625232084
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bayat, Sayeh
- Roe, Catherine M.
- SpringerLink (Online service)
Other Objects (12)
GPS driving: a digital biomarker for preclinical Alzheimer disease
APOE effects on regional tau in preclinical Alzheimer’s disease
An olfactory ‘stress test’ may detect preclinical Alzheimer’s disease
Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease
Preclinical Alzheimer’s dementia: a useful concept or another dead end?
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease
P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease
Brain reserve contributes to distinguishing preclinical Alzheimer’s stages 1 and 2
Sex/gender effects of glial reactivity on preclinical Alzheimer’s disease pathology
The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease
APP mouse models for Alzheimer's disease preclinical studies
GPS driving: a digital biomarker for preclinical Alzheimer disease
APOE effects on regional tau in preclinical Alzheimer’s disease
An olfactory ‘stress test’ may detect preclinical Alzheimer’s disease
Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease
Preclinical Alzheimer’s dementia: a useful concept or another dead end?
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease
P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease
Brain reserve contributes to distinguishing preclinical Alzheimer’s stages 1 and 2
Sex/gender effects of glial reactivity on preclinical Alzheimer’s disease pathology
The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease
APP mouse models for Alzheimer's disease preclinical studies
GPS driving: a digital biomarker for preclinical Alzheimer disease
APOE effects on regional tau in preclinical Alzheimer’s disease
An olfactory ‘stress test’ may detect preclinical Alzheimer’s disease
Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease
Preclinical Alzheimer’s dementia: a useful concept or another dead end?
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease
P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease
Brain reserve contributes to distinguishing preclinical Alzheimer’s stages 1 and 2
Sex/gender effects of glial reactivity on preclinical Alzheimer’s disease pathology
The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease